Literature DB >> 25684988

Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations.

M Carrier1, A Lazo-Langner2, S Shivakumar3, V Tagalakis4, P L Gross5, N Blais6, C A Butts7, M Crowther8.   

Abstract

Venous thromboembolism is a common complication in cancer patients, and thromboembolism is the second most common cause of death after cancer progression. A number of clinical practice guidelines provide recommendations for the management of cancer-associated thrombosis. However, the guidelines lack recommendations covering commonly encountered clinical challenges (for example, thrombocytopenia, recurrent venous thromboembolism, etc.) for which little or no evidence exists. Accordingly, recommendations were developed to provide expert guidance to medical oncologists and other health care professionals caring for patients with cancer-associated thrombosis. The current expert consensus was developed by a team of 21 clinical experts. For each identified clinical challenge, the literature in medline, embase, and Evidence Based Medicine Reviews was systematically reviewed. The quality of the evidence was assessed, summarized, and graded. Consensus statements were generated, and the experts voted anonymously using a modified Delphi process on their level of agreement with the various statements. Statements were progressively revised through separate voting iterations and were then finalized. Clinicians using these recommendations and suggestions should tailor patient management according to the risks and benefits of the treatment options, patient values and preferences, and local cost and resource allocations.

Entities:  

Keywords:  Venous thromboembolism; deep-vein thrombosis; pulmonary embolism; recommendations

Year:  2015        PMID: 25684988      PMCID: PMC4324343          DOI: 10.3747/co.22.2392

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  36 in total

1.  Safety and feasibility of a diagnostic algorithm combining clinical probability, d-dimer testing, and ultrasonography for suspected upper extremity deep venous thrombosis: a prospective management study.

Authors:  Ankie Kleinjan; Marcello Di Nisio; Jan Beyer-Westendorf; Giuseppe Camporese; Benilde Cosmi; Angelo Ghirarduzzi; Pieter W Kamphuisen; Hans-Martin Otten; Ettore Porreca; Anita Aggarwal; Marianne Brodmann; Maria Domenica Guglielmi; Matteo Iotti; Karin Kaasjager; Virginia Kamvissi; Teresa Lerede; Peter Marschang; Karina Meijer; Gualtiero Palareti; Frederick R Rickles; Marc Righini; Anne W S Rutjes; Chiara Tonello; Peter Verhamme; Sebastian Werth; Sanne van Wissen; Harry R Büller
Journal:  Ann Intern Med       Date:  2014-04-01       Impact factor: 25.391

Review 2.  Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis.

Authors:  Maria Cristina Vedovati; Federico Germini; Giancarlo Agnelli; Cecilia Becattini
Journal:  Chest       Date:  2015-02       Impact factor: 9.410

Review 3.  Accuracy of diagnostic tests for clinically suspected upper extremity deep vein thrombosis: a systematic review.

Authors:  M Di Nisio; G L Van Sluis; P M M Bossuyt; H R Büller; E Porreca; A W S Rutjes
Journal:  J Thromb Haemost       Date:  2010-02-06       Impact factor: 5.824

4.  Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy.

Authors:  C Luk; P S Wells; D Anderson; M J Kovacs
Journal:  Am J Med       Date:  2001-09       Impact factor: 4.965

5.  Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis.

Authors:  Philipp Hoffmann; Frieder Keller
Journal:  Eur J Clin Pharmacol       Date:  2011-11-17       Impact factor: 2.953

6.  The clinician's response to a report of an incidental pulmonary embolism detected on multidetector CT.

Authors:  James M Franklin; Najib Rahman; Fergus V Gleeson
Journal:  Postgrad Med J       Date:  2011-08-27       Impact factor: 2.401

7.  Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: a randomized trial.

Authors:  Marc A Rodger; Tim Ramsay; Martin MacKinnon; Margit Westphal; Philip S Wells; Brendan McCormick; Greg Knoll
Journal:  Am J Kidney Dis       Date:  2012-04-04       Impact factor: 8.860

8.  Unsuspected pulmonary emboli in lung cancer patients: the impact on survival and the significance of anticoagulation therapy.

Authors:  Jong-Mu Sun; Tae Sung Kim; Jeeyun Lee; Yeon Hee Park; Jin Seok Ahn; Hojoong Kim; O Jung Kwon; Kyung Soo Lee; Keunchil Park; Myung-Ju Ahn
Journal:  Lung Cancer       Date:  2009-12-14       Impact factor: 5.705

9.  A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study).

Authors:  M J Kovacs; S R Kahn; M Rodger; D R Anderson; R Andreou; J E Mangel; B Morrow; A M Clement; P S Wells
Journal:  J Thromb Haemost       Date:  2007-05-07       Impact factor: 5.824

10.  Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis.

Authors:  Ryma Ihaddadene; Grégoire Le Gal; Aurélien Delluc; Marc Carrier
Journal:  Thromb Res       Date:  2014-05-02       Impact factor: 3.944

View more
  12 in total

Review 1.  Venous thrombosis and cancer: from mouse models to clinical trials.

Authors:  Y Hisada; J E Geddings; C Ay; N Mackman
Journal:  J Thromb Haemost       Date:  2015-06-26       Impact factor: 5.824

2.  Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus.

Authors:  M Carrier; N Blais; M Crowther; P Kavan; G Le Gal; O Moodley; S Shivakumar; V Tagalakis; C Wu; A Y Y Lee
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

Review 3.  Challenging clinical scenarios for therapeutic anticoagulation: A practical approach.

Authors:  Kylee L Martens; Simone E Dekker; Megan Crowe; Thomas G DeLoughery; Joseph J Shatzel
Journal:  Thromb Res       Date:  2022-08-19       Impact factor: 10.407

4.  Clinical analysis of tumor and non-tumor patients complicated with pulmonary embolism.

Authors:  Hong Wang; Yuan Huang; Chun-Wei Xu; Li Lin
Journal:  Int J Clin Exp Med       Date:  2015-10-15

5.  Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.

Authors:  N A Zakai; R F Walker; R F MacLehose; T J Adam; A Alonso; P L Lutsey
Journal:  J Thromb Haemost       Date:  2018-10-24       Impact factor: 5.824

6.  A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making.

Authors:  Amy Johnston; Shu-Ching Hsieh; Marc Carrier; Shannon E Kelly; Zemin Bai; Becky Skidmore; George A Wells
Journal:  PLoS One       Date:  2018-11-09       Impact factor: 3.240

7.  Impact of oral anticoagulation choice on healthcare utilization for the primary treatment of venous thromboembolism.

Authors:  Pamela L Lutsey; Richard F MacLehose; J'Neka S Claxton; Rob F Walker; Terrence J Adam; Alvaro Alonso; Neil A Zakai
Journal:  Vasc Med       Date:  2020-07-27       Impact factor: 3.239

8.  Management of Chemotherapy-Induced Left Ventricular Dysfunction and Heart Failure in Patients With Cancer While Undergoing Cancer Treatment: The MD Anderson Practice.

Authors:  Anecita P Fadol
Journal:  Front Cardiovasc Med       Date:  2018-03-28

Review 9.  Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins.

Authors:  Alannah Smrke; Peter L Gross
Journal:  Front Med (Lausanne)       Date:  2017-08-28

Review 10.  Managing thrombosis in cancer patients.

Authors:  Tzu-Fei Wang; Ang Li; David Garcia
Journal:  Res Pract Thromb Haemost       Date:  2018-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.